Details

Autor(en) / Beteiligte

• Galli, Eugenio
• Sorà, Federica
• Di Gianfrancesco, Luca
• Giammarco, Sabrina
• Metafuni, Elisabetta
• Limongiello, Maria Assunta
• Innocenti, Idanna
• Autore, Francesco
• Laurenti, Luca
• Chiusolo, Patrizia
• Bacigalupo, Andrea
• Sica, Simona

Titel

Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia

Ist Teil von

• Supportive care in cancer, 2022-06, Vol.30 (6), p.4953-4959

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Hemorrhagic cystitis (HC) is a frequent complication of allogeneic hematopoietic stem-cell transplantation (HSCT). HC worsens transplant outcomes and patient wellbeing in terms of pain, hospitalization, and need for supportive care. A deeper understanding of the risk factors of HC may lead to more intensive prevention in high-risk patients. Methods In this report, we analyzed 237 consecutive patients who received HSCT with the aim of identifying possible risk factors for HC and their consequences, with a particular focus on transplant- and gender-related risk factors. Results HC occurred in 17% of patients, with a higher incidence in males (21% vs 11%, p  = 0.03). Risk factors identified for HC included age over 55 years, male recipient, HLA mismatch, reduced intensity conditioning, and cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis. Increased HC was seen in patients with grade II–IV acute GVHD and detectable BKV and JCV viruria. In a multivariate model, increased age remained significant ( p  = 0.013). Patients with HC had longer hospitalizations and increased non-relapse mortality (NRM). Among male recipients, independent risk factors for HC included age ( p  = 0.016) and prostate volume ( p  = 0.016). Prostatic hyperplasia (volume more than 40 cm 3 ) occurred in 33% of male patients, of which 32% developed HC (compared with 16% of patients without prostatic hyperplasia; p  = 0.032). Conclusions Age is the most important risk factor for HC. Additional potential risk factors include cyclophosphamide-based GVHD prophylaxis and HLA mismatch. Among male recipients, prostatic hyperplasia is an additional independent risk factor. As HC is common and associated with prolonged hospitalization, more intensive prophylactic strategies should be considered in high-risk patients.